ReviewFrontiers in immunology2025
Regulated programmed cell death in acute lung injury: from pathogenesis to therapy.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Curculigoside attenuates influenza virus-induced acute lung injury by modulating the Keap1/Nrf2 signaling pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Combining network pharmacology and experimental validation to demonstrate that salidroside alleviates acute lung injury by inhibiting ferroptosis via the MAPK/GPX4 pathway.Respiratory research · 2026Article
- miR-21-5p attenuates hyperoxia-induced lung injury by modulating YAP1-dependent ferroptosis.Frontiers in pharmacology · 2026Article
- The Role of Traditional Chinese Medicine in Acute Lung Injury: Targeting Programmed Cell Death.Drug design, development and therapy · 2026Review
- The Extracellular Matrix and the Immune System in Acute Lung Injury: Partners in Damage and Repair.Biomedicines · 2025Review
- Therapeutic effects of mesenchymal stromal cells transplantation in animal models of chronic obstructive pulmonary disease: a systematic review and meta-analysis of emphysema and lung inflammation models.Frontiers in cell and developmental biology · 2025Review
- The selective ERβ agonist AC 186 reduces polyinosinic:polycytidylic acid (poly I:C)-induced inflammatory responses in BEAS-2B lung epithelial cells.Frontiers in pharmacology · 2025Article
Corrections and comments
- Retracted
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute lung injury (ALI) is a common, life-threatening lung disease with a high mortality rate, primarily associated with acute and severe inflammation of the lungs. There are many factors that lead to ALI, and abnormally advanced regulated programmed cell death (RCD) is considered to be an important process in the pathological process of ALI. Various forms of RCD have been discovered in recent years, including apoptosis, necroptosis, autophagy, ferroptosis and pyroptosis. Unlike necrosis, RCD is an active cell death mediated by a series of gene expression events that is essential for eliminating unnecessary and damaged cells as well as defense mechanisms. Previous studies have shown that RCD has a strong relationship with ALI. Therefore, it is important to describe the role of RCD not only to enhance our understanding of the pathophysiological processes of ALI, but also to improve the functional recovery after ALI. This review reviews the roles and mechanisms of various RCD (apoptosis, pyroptosis, necroptosis, ferroptosis and autophagy) in ALI, and discusses the associations among various types of RCD. The aim is to explore the molecular mechanism behind SALI and find new targets for the treatment of ALI. This review will help us understand the various functions and mechanisms of RCD in the pathological process of ALI, and help us to treat various ALI of unknown etiology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.